Literature DB >> 34070984

Transformational Role of Medical Imaging in (Radiation) Oncology.

Catherine Coolens1,2,3,4,5, Matt N Gwilliam1, Paula Alcaide-Leon6, Isabella Maria de Freitas Faria7, Fabio Ynoe de Moraes8.   

Abstract

Onboard, real-time, imaging techniques, from the original megavoltage planar imaging devices, to the emerging combined MRI-Linear Accelerators, have brought a huge transformation in the ability to deliver targeted radiation therapies. Each generation of these technologies enables lethal doses of radiation to be delivered to target volumes with progressively more accuracy and thus allows shrinking of necessary geometric margins, leading to reduced toxicities. Alongside these improvements in treatment delivery, advances in medical imaging, e.g., PET, and MRI, have also allowed target volumes themselves to be better defined. The development of functional and molecular imaging is now driving a conceptually larger step transformation to both better understand the cancer target and disease to be treated, as well as how tumors respond to treatment. A biological description of the tumor microenvironment is now accepted as an essential component of how to personalize and adapt treatment. This applies not only to radiation oncology but extends widely in cancer management from surgical oncology planning and interventional radiology, to evaluation of targeted drug delivery efficacy in medical oncology/immunotherapy. Here, we will discuss the role and requirements of functional and metabolic imaging techniques in the context of brain tumors and metastases to reliably provide multi-parametric imaging biomarkers of the tumor microenvironment.

Entities:  

Keywords:  RECIST; brain cancer; imaging biomarker; microenvironment; quantitative imaging; radiation oncology; response

Year:  2021        PMID: 34070984     DOI: 10.3390/cancers13112557

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  88 in total

1.  Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.

Authors:  Hee Ho Chu; Seung Hong Choi; Inseon Ryoo; Soo Chin Kim; Jeong A Yeom; Hwaseon Shin; Seung Chai Jung; A Leum Lee; Tae Jin Yoon; Tae Min Kim; Se-Hoon Lee; Chul-Kee Park; Ji-Hoon Kim; Chul-Ho Sohn; Sung-Hye Park; Il Han Kim
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

Review 2.  Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies.

Authors:  Nishant Verma; Matthew C Cowperthwaite; Mark G Burnett; Mia K Markey
Journal:  Neuro Oncol       Date:  2013-01-16       Impact factor: 12.300

3.  Histogram Analysis of Diffusion-Weighted MR Imaging as a Biomarker to Predict Survival of Surgically Treated Colorectal Cancer Patients.

Authors:  Yumiko Takahashi; Koichi Hayano; Gaku Ohira; Shunsuke Imanishi; Toshiharu Hanaoka; Hiroki Watanabe; Atsushi Hirata; Yohei Kawasaki; Hideaki Miyauchi; Hisahiro Matsubara
Journal:  Dig Dis Sci       Date:  2020-05-14       Impact factor: 3.199

4.  Cerebral blood flow determination by rapid-sequence computed tomography: theoretical analysis.

Authors:  L Axel
Journal:  Radiology       Date:  1980-12       Impact factor: 11.105

5.  The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs.

Authors:  Hans Wahn; Jürgen Wolf; Florian Kram; Stefan Frantz; Jens A Wagner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-07-29       Impact factor: 4.733

6.  Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.

Authors:  Anwar R Padhani; Guoying Liu; Dow Mu Koh; Thomas L Chenevert; Harriet C Thoeny; Taro Takahara; Andrew Dzik-Jurasz; Brian D Ross; Marc Van Cauteren; David Collins; Dima A Hammoud; Gordon J S Rustin; Bachir Taouli; Peter L Choyke
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

7.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

8.  Glioma recurrence versus radiation necrosis? A pilot comparison of arterial spin-labeled, dynamic susceptibility contrast enhanced MRI, and FDG-PET imaging.

Authors:  Yelda Ozsunar; Mark E Mullins; Kenneth Kwong; Fred H Hochberg; Christine Ament; Pamela W Schaefer; R Gilberto Gonzalez; Michael H Lev
Journal:  Acad Radiol       Date:  2010-01-12       Impact factor: 3.173

Review 9.  Overview: progression-free survival as an endpoint in clinical trials with solid tumors.

Authors:  Ronald L Korn; John J Crowley
Journal:  Clin Cancer Res       Date:  2013-05-15       Impact factor: 12.531

Review 10.  Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials.

Authors:  Amita Shukla-Dave; Nancy A Obuchowski; Thomas L Chenevert; Sachin Jambawalikar; Lawrence H Schwartz; Dariya Malyarenko; Wei Huang; Susan M Noworolski; Robert J Young; Mark S Shiroishi; Harrison Kim; Catherine Coolens; Hendrik Laue; Caroline Chung; Mark Rosen; Michael Boss; Edward F Jackson
Journal:  J Magn Reson Imaging       Date:  2018-11-19       Impact factor: 5.119

View more
  1 in total

1.  Implications of the Harmonization of [18F]FDG-PET/CT Imaging for Response Assessment of Treatment in Radiotherapy Planning.

Authors:  Elisa Jiménez-Ortega; Raquel Agüera; Ana Ureba; Marcin Balcerzyk; Amadeo Wals-Zurita; Francisco Javier García-Gómez; Antonio Leal
Journal:  Tomography       Date:  2022-04-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.